SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

Six-year follow-up from a trial comparing surgery with TAVR in low-risk patients showed no difference in major events, but ...

Two major players are vying for women’s hearts, but it’s not as romantic as it sounds. After Medtronic put forward a head-to-head study in April showing its transcatheter aortic valve replacement ...

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration recently cleared the line of catheter-based heart valves, which includes Sapien ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At 7 years, there was no difference in clinical outcomes ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...